Login to Your Account

Other News To Note

Wednesday, November 20, 2013

• Wuxi Pharmatech Inc., of Shanghai, said its wholly owned subsidiary entered a supply arrangement with Pharmacyclics Inc., of Sunnyvale, Calif., for Imbruvica (ibrutinib), the mantle-cell lymphoma therapy approved this month. Terms were not disclosed.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription